NCT03281382View on ClinicalTrials.gov

Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

May 28, 2019

Study Completion Date

May 28, 2019

Conditions
Metastatic Pancreatic Cancer
Interventions
BIOLOGICAL

Ad5-yCD/mutTKSR39rep-hIL12

Oncolytic adenovirus expressing two suicide genes and human IL-12

Trial Locations (1)

48202

Henry Ford Hospital, Detroit

All Listed Sponsors
lead

Henry Ford Health System

OTHER

NCT03281382 - Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter